Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...
Tasha Boerner, 53, a Democrat and incumbent state Assembly member, is running for re-election to California’s 77th Assembly ...
Steve Padilla, 59, a Democrat and incumbent state senator, is running for re-election to California’s 32nd Senate District ...
There comes a point in everybody’s life when things that they were a part of are presented as history, and for the 8-bit ...
EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis - Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted ...
The six candidates on the ballot for the Sioux Falls School Board debated opt-outs, student test scores and the district’s ...
Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of- ...
In April 2026, BioAge reported positive topline data from the Phase 1 trial of BGE-102, its oral, brain-penetrant NLRP3 inhibitor, including a newly announced 60 mg once-daily cohort in participants ...
UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.48244. Operator: Good day, and thank you for standing by. Welcome to the UroGen Pharma Q1 2026 Results ...
Ladies and gentlemen, welcome to the Rheinmetall AG Q1 2026 Conference Call. I'm [ Iruna ], the Chorus Call operator. [Operator Instructions] The conference must not be recorded for publication or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results